Biotech Values

[DewDiligence]

Cross-town rival Novartis, which recently shrugged off drug-price cuts across Europe to raise its full-year sales goal on the back of strong demand for its newest products, said it had no need to make similar cost cuts. “If it were necessary, [but] it isn't,” Novartis Chairman Daniel Vasella told Reuters at a business event in Basel when asked if Novartis would take similar savings measures to Roche's.

http://www.reuters.com/article/idCNLDE68203L20100903